DB06498InvestigationalVaccines
According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and...
- Primary indication
- Investigated for use/treatment in lung cancer.Curator reviewed
- Code names
- L523S
What you can answer from here — as of April 23, 2025
Which companies are running trials of L523S, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account